key: cord-0278353-aufn5nkt
authors: Kim, Y.; Varosanec, M.; Kosa, P.; Bielekova, B.
title: Confounder-adjusted MRI-based predictors of multiple sclerosis disability
date: 2022-04-19
journal: nan
DOI: 10.1101/2022.04.18.22273974
sha: 75e42aea40882445666199b418123400a4a82ef0
doc_id: 278353
cord_uid: aufn5nkt

Introduction: Both aging and multiple sclerosis (MS) cause central nervous system (CNS) atrophy. Excess brain atrophy in MS has been interpreted as accelerated aging. Current paper tests an alternative hypothesis: MS causes CNS atrophy by mechanism(s) different from physiological aging. Thus, subtracting effects of physiological confounders on CNS structures would isolate MS-specific effects. Methods: Standardized brain MRI and neurological examination were acquired prospectively in 649 participants enrolled in ClinicalTrials.gov Identifier: NCT00794352 protocol. CNS volumes were measured retrospectively, by automated Lesion-TOADS algorithm and by Spinal Cord Toolbox, in a blinded fashion. Physiological confounders identified in 80 healthy volunteers were regressed out by stepwise multiple linear regression. MS specificity of confounder-adjusted MRI features was assessed in non-MS cohort (n=160). MS patients were randomly split into training (n=277) and validation (n=132) cohorts. Gradient boosting machine (GBM) models were generated in MS training cohort from unadjusted and confounder-adjusted CNS volumes against four disability scales. Results: Confounder adjustment highlighted MS-specific progressive loss of CNS white matter. GBM model performance decreased substantially from training to cross-validation, to independent validation cohorts, but all models predicted cognitive and physical disability with low p-values and effect sizes that outperforms published literature based on recent meta-analysis. Models built from confounder-adjusted MRI predictors outperformed models from unadjusted predictors in the validation cohort. Conclusion: GBM models from confounder-adjusted volumetric MRI features reflect MS-specific CNS injury, and due to stronger correlation with clinical outcomes compared to brain atrophy these models should be explored in future MS clinical trials.

training (n=277) and validation (n=132) cohorts. Gradient boosting machine (GBM) models 23 were generated in MS training cohort from unadjusted and confounder-adjusted CNS volumes 24 against four disability scales. 25

Results: Confounder adjustment highlighted MS-specific progressive loss of CNS white matter. 26 GBM model performance decreased substantially from training to cross-validation, to 27 independent validation cohorts, but all models predicted cognitive and physical disability with 28 low p-values and effect sizes that outperforms published literature based on recent meta-analysis. 29

Models built from confounder-adjusted MRI predictors outperformed models from unadjusted 30 predictors in the validation cohort. 31 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint

• Developed GBM models should be explored in future MS clinical trials 48 49

All raw data and script used for all analyses will be provided after being accepted. 51 52 Author Contribution 53 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint

Scientific advancements in Multiple Sclerosis (MS) translated into the development of disease-73 modifying treatments (DMTs) that effectively inhibit central nervous system (CNS) tissue 74 destruction and clinical disability development if given to a young subject shortly after disease 75 onset. Unfortunately, these treatments lose efficacy with advancing age of patients. On a group 76 level, they show no statistically-significant inhibition of disability progression in subjects older 77 than 54 years (Weideman et al., 2017b) . To develop more effective MS treatments, we need 78 sensitive outcomes that can objectively quantify CNS tissue destruction and development of 79 disability against active comparator, in reasonably sized cohorts. Additionally, assembling several of these changing brain volumes into a single model using 90 machine-learning (ML) algorithm(s) may further increase effect size. 91

In terms of specificity, brain atrophy also occurs during natural aging (Rocca et al., 2017) . In 93 what we identified as the largest published study of healthy volunteers (HV; n=2790), 94 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint physiological confounders such as age, gender and predicted intracranial volume (PIV), 95 explained a very high proportion of variance in thalamic (>60%), caudate (>40%) and 96 ventricular (57%) volumes (Potvin et al., 2016) . In fact, ML-derived models can predict 97 chronological age (with a mean absolute error of +/-5 years (Cole et al., 2017) ) using just brain 98 MRI predictors. A study from European Magnetic Resonance Imaging in MS (MAGNIMS) 99 consortium (Cole et al., 2020) explored the difference between chronological and brain MRI-100 predicted age, termed as Brain-predicted Age Difference (Brain-PAD). The study demonstrated 101 that 1204 MS patients had on average 6 years higher Brain-PAD compared to HV, without 102 significant differences among MS subtypes (i.e., relapsing-remitting [RRMS], secondary-103

[SPMS] and primary-progressive MS [PPMS]). Brain-PAD also correlated with disability 104 measured by Expanded Disability Status Scale (EDSS). Although no effect size was provided, 105 the associated figures suggested that Brain-PAD explains < 10% of EDSS variance. The authors 106 concluded that MS is associated with accelerated brain aging (Cole et al., 2020 

The study design is shown in Figure 1 . 134 135

All patients were prospectively recruited into the protocol "Comprehensive Multimodal Analysis 137 of Neuroimmunological Diseases of the Central Nervous System" (Clinicaltrials.gov Identifier: 138 NCT00794352) and provided written informed consent. The inclusion criteria for patient cohort 139 are age at least 12 years and clinical symptoms, CSF results or MRI imaging suggestive of 140 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Figure S1 . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint Before unblinding, we performed quality control of volumetric data. A total of 62 (8.7%) MRI 188 scans was excluded due to inaccurate segmentation of brain structures, low image quality, and 189 motion artifacts, leaving 649 scans for the final dataset in study. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint

biomarkers were analyzed using unpaired two-samples Wilcoxon signed-rank test in R (Team, 210 1969) . validation to select the optimal number of trees that will prevent each model from overfitting. 230 Improvement in mean squared error from splits within each individual tree and the average of 231 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. Package: stats (Team, 1969) and rstatix (Kassambara, 2021) ; and Concordance Correlation 254 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

As shown in Supplementary Figure S1, HV cohort was significantly younger than MS (i.e., 299

Median 40.4 years vs Median=52.4 years; p=1.24e-7). Because age exerted significant effects on 300 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint many CNS volumes, subtracting the variance explained by age diminished differences between 301 HV and MS cohorts in most CNS volumetric biomarkers (Figure 3) . The greatest decrease in 302 effect size was seen for thalamus, caudate and brain parenchymal fraction (BPFr) -consistent 303 with the reported strong effect of physiological aging on these CNS structures. Supplementary Table S2 . 345 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint observed stronger effect sizes for unadjusted models ( Figure 6A and Supplementary Table S2) . 347

But for SDMT, the confounder-adjusted model slightly outperformed the unadjusted model. showcasing the poor estimate of model's performance depending on the training cohort splits. 355

Nevertheless, cross-validation medians had uniformly lower effect sizes than the training cohort; 356 the decrease in effect sizes was substantial (between 40-60% for R^2). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint

We conclude that training cohort results are poor predictors of the model's performance in the 370 independent validation cohort: they consistently and dramatically over-estimate final effect sizes. 371

The stronger validation performance of confounder-adjusted models supports our hypothesis that Before we discuss our findings, we want to point out following limitations: our HV cohort is 389 relatively small and the Lesion-TOADS automated segmentation algorithm, implemented from 390 the inception of our natural history protocol, has relatively narrow adoption. Despite the 391 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. structures. Similarly, we saw that these brain structures were selected by most GBM models, 431 with predictably higher influence of WM volumes in the models based on confounder-adjusted 432 biomarkers. 433 434 Although brain structures with higher effect sizes in differentiating MS from HV were more 435 important in GBM models of disability, this was not true for SC CSA. C1-2 SC CSA had 436 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint marginal effect size and p-value in differentiating MS from HV, but it had relatively high 437 univariate correlations with disability outcomes and, concordantly, was selected by all GBM 438 models of physical disability (i.e., EDSS, CombiWISE, and NeurEx) as leading MRI feature. 439

These results are consistent with clinical observations that MS involvement of SC is the 440 dominant driver of physical disability, especially ambulation. We believe that relatively weak 441 effect size in differentiating MS from HV for SC CSA resides in the technical difficulty of 442 scanning such small structure. We did not have dedicated SC MRIs for most subjects, and 443 artifacts due to CSF pulsation, heart beats and breathing are likely accentuated by using brain 444 coil, rather than dedicated SC coil with protocol optimized for SC imaging. 445

Additionally, age was selected as the strongest variable in confounder-adjusted models. This 447 poses a question whether we gained anything by adjusting MRI features for confounders. First, 448 confounder adjustment did enhance validation performance of the models. Second, in unilateral 449 correlations, age correlates with disability outcomes with effect sizes comparable to strongest 450 MRI biomarkers. However, this does not mean that effect of age on MS disability is 451 pathophysiologically identical to normal aging. For example, age effects on immunity may 452 become relevant only in patients with intrathecal inflammation. Separating age from its 453 confounding effect on MRI biomarkers may lead to models that are more responsive to MS 454 treatment effects, a potential hypothesis for future longitudinal studies. Using an associated website that allow users to dynamically explore this rich dataset, we 459 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint identified 40 papers that used MRI biomarkers to model EDSS as ordinal scale and reported p-460 values, and 20 papers that reported effect sizes as R^2. Many studies overestimate effect sizes 461 from using small cohorts or failing to implement methodological design that limit bias (Button et 462 al., 2013; Ioannidis, 2005 Ioannidis, , 2008 . Thus, the meta-analysis scored methodological rigor of 463 reviewed studies by grading 7 criteria: 1. Blinding, 2. Defined strategy to deal with outliers, 3. (n=114). Current study fulfills 7/7 criteria of methodological rigor and is the only study that 478 includes independent validation cohort. For the confounder-adjusted EDSS model, the training 479 cohort R^2 is 0.69 (p=3.8e-43). Median cross-validation R^2 is 0.29 and the independent 480 validation cohort R^2 is 0.26 (p=2.4e-08). To our knowledge, this is the strongest reported effect 481 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. modeling studies, the independent validation must be considered a gold standard. This is 499 extremely important, as only 15% of published MS models used any validation strategy and only 500 8% used independent validation. 501 502

In conclusion, our final models outperform correlations of any single MRI biomarker with 503 clinical outcomes. These models are therefore likely more sensitive imaging outcomes and 504 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint should be explored in future clinical trials, especially when targeting older subjects with 505 progressive MS who no longer form acute MS lesions. The MAGNIMS consortium has available 506 datasets to quantify possible loss of sensitivity due to inter-scanner/inter-protocol variance on 507 such ML-based models in comparison to a single MRI biomarker. 508 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Resulting quantitative MRI biomarkers were assessed for quality to identify intra-and inter-520 individual outliers. Identified outliers were manually checked and scans with incorrect 521 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Gradient boosting machine (GBM) algorithm was applied to the training cohort using 529 confounder-adjusted (and unadjusted) MRI features as predictors to derive two sets of models for 530 the four stated clinical outcomes. 11: Models were further optimized in the training cohort using 531 10-fold cross validation. 12: Resulting eight models were applied to the independent validation 532 cohort that did not contribute, in any way, to the generation or optimization of the models. 533 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) corner is resulting radar chart that show proportional weights of the applied confounder 539 adjustment, with confounders with lowest weights (i.e., the innermost circle) representing zeros. 540 C. Univariate linear regression models between each tested confounder on x-axis (first 5 graphs) 541 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) statistical significance. The difference between MS and HV was partially driven by confounder 557 differences in majority of these MRI features (6/10). Thus, the applied adjustment decreased the 558 ability of these features to differentiate MS from HV. On the other hand, three measurements of 559 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint correlations of MRI features with age, while it generally strengthened correlations of brain 569 parenchymal fraction (BPFr) with remaining MRI features. 570 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint colors. Correlation p-values indicate statistical significance (*P < 0.05, **P < 0.01, and ***P < 578 0.001). Additional descriptive statistics are shown in Supplementary Table S1 . 579 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint 580 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint

Thalamic Injury and Cognition in Multiple Sclerosis

Molecular models 600 of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms. medRxiv

Validity 603 of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple 604 sclerosis

Smartphone Level Test Measures Disability in Several Neurological 607 Domains for Patients With Multiple Sclerosis

Power failure: why small sample size undermines the reliability of neuroscience

Longitudinal Assessment of Multiple Sclerosis with the Brain-615

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Increased 619 brain-predicted aging in treated HIV disease

MRI correlates of clinical disability and hand-motor performance in 622 multiple sclerosis phenotypes

SCT: Spinal Cord Toolbox, an open-source software for processing spinal 625 cord MRI data

2020. gbm: Generalized Boosted 627 Regression Models

Magnetic Resonance Imaging in Multiple Sclerosis

Spring Harbor perspectives in medicine 8, a028969

Why most published research findings are false

Why most discovered true associations are inflated

Worse Physical Disability Is Associated With the Expression of PD-1 on Inflammatory

Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow 638 changes driven by brain atrophy

rstatix: Pipe-Friendly Framework for Basic Statistical Tests

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

NeurEx: digitalized neurological examination offers a novel high-resolution disability scale

Rating neurologic impairment in multiple sclerosis. An expanded disability 644 status scale (EDSS)

Current status and future opportunities in modeling 646

Assessment of Smartphone-Based Spiral Tracing in Multiple Sclerosis Reveals Intra-Individual 652

Reproducibility as a Major Determinant of the Clinical Utility of the Digital Test

Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a 659 prospective multicenter trial

Smartphone-661 based symbol-digit modalities test reliably captures brain damage in multiple sclerosis

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Alzheimer's Disease Neuroimaging, I., 664 2016. Normative data for subcortical regional volumes over the lifetime of the adult human 665 brain

Brain MRI atrophy quantification 668 in MS: From methods to clinical application

A topology-670 preserving approach to the segmentation of brain images with multiple sclerosis lesions

2021. DescTools: Tools for Descriptive Statistics

Associations 682 of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

RStudio: Integrated Development for R

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Disease Severity Scale Predicts Future Accumulation of Disability

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

Impact of Age on Multiple Sclerosis Disease Activity and 695

Progression

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101/2022.04.18.22273974 doi: medRxiv preprint